Exercise and Life Functioning in Patients with Congestive Heart Failure ; A Rehabilitation Cohort Study.

Exercise and Life Functioning in Patients with Congestive Heart Failure ; A Rehabilitation Cohort Study. - Exercise and Life Functioning in Patients with Congestive Heart Failure ; A Rehabilitation Cohort Study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000000885

Enrollment

500

Registered

2007-12-01

Start date

2008-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with congestive heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CHF patients with NYHA classification II to III who hospitalized due to acute exacerbation with ischemic heart diesase, cardiomyopathy, hypertension, valvular disease and arrhythmia, and an left ventricular ejection fraction 40% or less or B-type natriuretic peptide (BNP) levels more than 80pg/ml.

Exclusion criteria

Exclusion criteria: No.1-7 apply to all participants and No.1-18 apply to exercise group. The patient who; 1. underwent cardiac surgery during hospitalization. 2. can not walk over 50 meters. 3. has congnitive dysfunction(Mini Mental State Examination<18points). 4. has chronic obstructive pulmonary disease. 5. has psychiatry disorder. 6. has other disease that require hospitalization. 7. does not agree to participate in this study. 8. has severe renal dysfunction(Cr>2.3mg/dl,BUN>50mg/dl). 9. has anemia (Hb<9.0g/dl). 10. has uncontrolled rapid ventricular tachycardia (>180bpm,ICD firing>1/month). 11. has uncontrolled diabetes mellitus (HbA1c>9%). 12. has low blood pressure (SBP<80mmHg or proportional pulse pressure<20% of SBP). 13. has uncontrolled blood presure (SBP>160mmHg or DBP>100mmHg) 14. has HR<50bpm or HR>100bpm. 15. has anginal symptom. 16. has new atrial fibrilation. 17. has moderate to sever aortic valvular stenosis, or sever mitral valve regurgitation. 18. has hypertrophic obstructive cardiomyopathy.

Design outcomes

Primary

Measure	Time frame
Life functioning measure	—

Secondary

Measure	Time frame
Readmission or death Depressive symptoms	—

Countries

Japan

Contacts

Public ContactYAMADA SUMIO

Nagoya University Yamada Labolatory

052-719-1346

Outcome results